On ECHEMI
Home > Drugs > Multiple Myeloma
Multiple Myeloma
Myeloma (also known as plasma cell tumor) is a malignant tumor originating from plasma cells in the bone marrow. It is a common malignant tumor. It can be divided into single and multiple, with the latter being more common. Multiple myeloma, also known as cellular myeloma (Multiple myeloma, referred to as MM), is caused by the malignant transformation of plasma cells that synthesize and secrete immunoglobulins. The proliferation of a large number of monoclonal malignant plasma cells easily involves soft tissues. In the late stage, there may be extensive metastasis, but rarely lung metastasis. It is more common in the spine, accounting for 10% of primary spinal tumors, and is more common in the lumbar spine. The age of onset is mostly over 40 years old, and the ratio of men to women is about 2:1. It is more common in men over 40 years old, and the common sites are the spine, ribs, skull, sternum, etc.
  • Site of disease:

    whole body
  • Infectious :

    Not contagious
  • Frequent population:

    Middle-aged and elderly people
  • Related symptoms:

    Bone pain bleeding tendency recurrent infection kidney damage hepatosplenomegaly
Related Drugs
Lenalidomide capsules
Indication: Multiple myeloma, myelodysplastic syndrome
Bortezomib for injection
Indication: 1. This product is used to treat patients with multiple myeloma who have received at least two treatments before using this product and whose disease is still progressing during the most recent treatment. 2. The effectiveness of this product is based on its effective rate. There is no clinical controlled trial to prove its clinical benefits, such as improvement in survival rate.
Bortezomib for injection
Indication: 1. This product is used to treat patients with multiple myeloma who have received at least two treatments before using this product and whose disease is still progressing during the most recent treatment. 2. The effectiveness of this product is based on its effective rate. There is no clinical controlled trial to prove its clinical benefits, such as improvement in survival rate.
Bortezomib for injection
Indication: 1. This product is used to treat patients with multiple myeloma who have received at least two treatments before using this product and whose disease is still progressing during the most recent treatment. 2. The effectiveness of this product is based on its effective rate. There is no clinical controlled trial to prove its clinical benefits, such as improvement in survival rate.
Bortezomib for injection
Indication: 1. This product is used to treat patients with multiple myeloma who have received at least two treatments before using this product and whose disease is still progressing during the most recent treatment. 2. The effectiveness of this product is based on its effective rate. There is no clinical controlled trial to prove its clinical benefits, such as improvement in survival rate.
Bortezomib for injection
Indication: 1. This product is used to treat patients with multiple myeloma who have received at least two treatments before using this product and whose disease is still progressing during the most recent treatment. 2. The effectiveness of this product is based on its effective rate. There is no clinical controlled trial to prove its clinical benefits, such as improvement in survival rate.
Ubenimex
Indication: It can enhance immune function and be used for adjuvant therapy of anti-cancer chemotherapy and radiotherapy, immune deficiency in the elderly, etc. It can be used in combination with chemotherapy, radiotherapy and in patients with leukemia, multiple myeloma, myelodysplastic syndrome, hematopoietic stem cell transplantation, and other solid tumors.
Manufacturer:

ShenZhen Main Luck Pharmaceuticals Inc

Ubenimex
Indication: It can enhance immune function and be used for adjuvant therapy of anti-cancer chemotherapy and radiotherapy, immune deficiency in the elderly, etc. It can be used in combination with chemotherapy, radiotherapy and in patients with leukemia, multiple myeloma, myelodysplastic syndrome, hematopoietic stem cell transplantation, and other solid tumors.
Ubenimex
Indication: It can enhance immune function and be used for adjuvant therapy of anti-cancer chemotherapy and radiotherapy, immune deficiency in the elderly, etc. It can be used in combination with chemotherapy, radiotherapy and in patients with leukemia, multiple myeloma, myelodysplastic syndrome, hematopoietic stem cell transplantation, and other solid tumors.
Manufacturer:

Sichuan Qingmu Pharmaceutical Co., Ltd.

Ubenimex Capsules
Indication: This product can enhance immune function and is used for adjuvant therapy of anti-cancer chemotherapy and radiotherapy, elderly immune deficiency, etc. It can be used in conjunction with chemotherapy, radiotherapy and in combination with leukemia, multiple myeloma, myelodysplastic syndrome, hematopoietic stem cell transplantation, and other solid tumor patients.
Manufacturer:

Sichuan Luye Pharmaceutical Industry Co., Ltd.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.